Lucid Diagnostics Inc. (LUCD) Stock Rises on Q4 2025 Earnings

Lucid Diagnostics Inc. (LUCD) reported quarterly results with notable top-line growth alongside continued losses:

Total revenue: $1.5 million (+25.7% year-over-year).

Gross profit (loss): -$356 thousand (-62.5% year-over-year).

Operating profit (loss): -$14.0 million (+13.2% year-over-year).

Net income attributable to common shareholders: -$16.3 million (+40.9% year-over-year).

Diluted loss per share: -$0.10 (-136.7% year-over-year).

Balance sheet and cash flow highlights:

Operating cash flow: -$12.6 million (+27.4% year-over-year).

Purchases of property, plant and equipment: -$51 thousand (-80.3% year-over-year).

Cash and cash equivalents: $34.7 million (+55.2% year-over-year).

Total liabilities: $29.5 million (+16.5% year-over-year).

Cost of sales: $1.9 million (-13.3% year-over-year).

Market reaction and comparison to expectations:

Revenue of $1.5 million exceeded the consensus estimate of $1.39 million by about 8.4%.

Diluted loss per share of -$0.10 was marginally better than the estimate of -$0.10.

Shares moved about 5.82% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Lucid Diagnostics Inc. Hedge Fund Activity

We have seen 49 institutional investors add shares of Lucid Diagnostics Inc. stock to their portfolio, and 37 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AWM INVESTMENT COMPANY, INC. removed 2,990,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,259,645
GHISALLO CAPITAL MANAGEMENT LLC removed 2,960,066 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,226,471
ALYESKA INVESTMENT GROUP, L.P. removed 1,383,116 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,507,596
ABERDEEN GROUP PLC added 957,894 shares (+38.3%) to their portfolio in Q4 2025, for an estimated $1,044,104
BLACKROCK, INC. added 643,346 shares (+17.5%) to their portfolio in Q4 2025, for an estimated $701,247
LUMINUS MANAGEMENT LLC removed 541,836 shares (-59.4%) from their portfolio in Q4 2025, for an estimated $590,601
RENAISSANCE TECHNOLOGIES LLC added 532,894 shares (+181.5%) to their portfolio in Q4 2025, for an estimated $580,854

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Lucid Diagnostics Inc. Analyst Ratings

Wall Street analysts have issued reports on $LUCD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Ascendiant Capital issued a "Buy" rating on 12/10/2025
Needham issued a "Buy" rating on 11/13/2025

To track analyst ratings and price targets for Lucid Diagnostics Inc., check out Quiver Quantitative's $LUCD forecast page.

Lucid Diagnostics Inc. Price Targets

Multiple analysts have issued price targets for $LUCD recently. We have seen 2 analysts offer price targets for $LUCD in the last 6 months, with a median target of $5.625.

Here are some recent targets:

Edward Woo from Ascendiant Capital set a target price of $8.25 on 12/10/2025
Mike Matson from Needham set a target price of $3.0 on 11/13/2025